Across TCGA pan-cancer cohorts, COX20 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated COX20 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher COX20 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COX20 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where COX20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	29	view →
PDAC	DFS	Quartile	All	0.256	0.667	<.001	21	view →
LSCC	OS	Median	All	1.000	0.923	.012	9	view →
LUAD	DFS	Median	II,III,IV	0.261	0.703	.034	3	view →
GBM	OS	Quartile	All	0.933	0.724	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: COX20 tumor-vs-normal RNA expression · all COX20 data types